Combined dopamine (D2) and serotonin (5-HT2) receptor antagonist. Prepn: S. Umio et al., DE 1907670; eidem, US 3704245 (1969, 1972 both to Fujisawa); I. Ueda et al., Chem. Pharm. Bull. 26, 3058 (1978). Pharmacology: S. Uchida et al., Arzneim.-Forsch. 29, 1588 (1979). Pharmacokinetics and metabolism: K. Noda et al., ibid. 1595. Toxicology: K. Fukuhara et al., ibid. 1600. Effects on serotonin receptors: A. Czyrak et al., Pharmacopsychiatry 26, 53 (1993). GC-MS determn in plasma: O. Tanaka et al., Ther. Drug Monit. 18, 294 (1996). Clinical trials in schizophrenia: C. Barnas et al., Int. Clin. Psychopharmacol. 7, 23 (1992); A. Meyer-Lindenberg et al., Pharmacopsychiatry 30, 35 (1997).
Antipsychotic.
Antipsychotic; Other Tricyclics; Serotonin-Dopamine Antagonist